Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited (Emcure) is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules (both softgel capsules and hard-gel capsules) and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals.

Emcure Pharmaceuticals was established in 1981 by Satish Mehta, who began the company with a bank loan of ₹3 lakh (about US$35,000 then) after graduating from IIM-A. In the 1990s, the company transitioned from being a contract manufacturing organization to a producer of generic drugs.

In 2006, Emcure signed license agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir as part of their Global Access Programs.

In 2012, Roche signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.

In 2013, Emcure established a health foods venture in partnership with cricketer MS Dhoni, and Dhoni was signed up as Emcure's brand ambassador.

In 2014, Blackstone sold its 13% stake in Emcure to Bain Capital.

In 2021, Emcure demerged its US-based business, including subsidiary Heritage Pharmaceuticals, into a new company called Avet Lifesciences.

In 2024, Emcure launched its initial public offering, and listed on NSE and BSE.